Rob Arnold
执行副总裁
专长:
"Rob Arnold 在欧洲、北美和亚洲拥有 30 多年的咨询和行政领导经验，为生命科学领域中一些最具挑战性的业务情境制定创造性解决方案。他负责创新和转型工作，比如负责一些大型生命科学公司的研发组合管理和重新定位工作。
Rob 在行业论坛、商学院和专业协会就生命科学战略进行演讲，并发表了多篇专业论文。
他拥有达特茅斯学院埃莫斯·塔克工商管理学院的 MBA 学位和剑桥大学的文学硕士学位。"
Articles by Rob Arnold
Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare
Authors: Prachi Singh, Senior Consultant; Robin Arnold, EVP, APAC Consulting Unlock the future of healthcare with our white paper, “Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare.” Discover the essential components of pricing AI/MedTech solutions and crafting compelling value propositions that resonate with stakeholders, including payers, patients, and physicians. Explore real-world examples, […]
Navigating the Patient Journey: Understanding, Challenges, and Solutions in Patient Journey Mapping
EVERSANA’s APAC Authors: Ankit Kulshrestha, Robin Arnold This POV explores the intricacies of Patient Journey Mapping, detailing its significance, challenges, and solutions. Patient journey mapping is a comprehensive discipline that traces a patient’s entire healthcare journey, from initial symptoms to treatment and beyond. Understanding this journey is imperative for pharmaceutical companies, enabling them to address challenges […]
Reframing the Challenges of Access and ROI
Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see evidence of corporate responsibility, for which pharmaceuticals’ surrogate measure is access. While companies such as Novo Nordisk and UCB […]
WEBINAR: Sustainability in Pharma: Access and Financial Returns
In addition to the global disruption caused by COVID-19, pharma faces additional pressure to adopt digital technologies, transform long-standing business practices, and accelerate timelines to deliver value for HCPs and patients. Not to mention, the specialty pipeline continues to grow, but therapies for rare diseases are facing significant access challenges. In this webinar, EVERSANA’s Rob […]
How Do You Know Your Portfolio Process Is Adding Value?
In 1998, Rob Arnold, Executive Vice President, teamed with some colleagues to publish an article in the Harvard Business Review that highlighted the practical results obtained by applying modern R&D portfolio thinking to SmithKline Beecham’s late-stage assets. SB publicly claimed that the review process had added $2.6 billion in value to the corporation. That team […]